KORU Medical Systems Partners with Pharma Giant for Novel Subcutaneous Immunoglobulin Trial; Poised for Breakthrough in Patient-Centric Infusion Solutions
MAHWAH, N.J. - KORU Medical Systems, Inc. (NASDAQ: KRMD), a leading medical technology company specializing in the development and commercialization of patient-centric large volume subcutaneous infusion solutions, has announced a groundbreaking clinical supply agreement with a prominent pharmaceutical partner. This collaboration will facilitate the Phase 3 trial of a novel subcutaneous immunoglobulin (SCIg) drug, with KORU Medical’s custom device playing a vital role in delivering this groundbreaking therapy. The agreement is a significant milestone for both KORU Medical and the wider medical technology industry, paving the way for a future where patient-centric infusion solutions are the norm.
Subcutaneous immunoglobulin therapy has emerged as an effective treatment for a range of immunodeficiency disorders, including primary immunodeficiencies and certain autoimmune disorders. By delivering immunoglobulin directly into the subcutaneous tissue, rather than intravenously, patients can experience improved quality of life, reduced hospital visits, and enhanced safety.
Under a previous agreement, KORU Medical successfully developed a custom product for the Phase 3 trial. The collaboration enables the pharmaceutical partner to leverage KORU Medical’s expertise in devising innovative infusion solutions tailored to the unique needs of the trial. KORU Medical’s custom device will allow the precise and controlled delivery of the novel SCIg drug to patients, ensuring optimal therapeutic outcomes and enhanced patient comfort.
This clinical supply agreement signifies a major milestone for KORU Medical, as it solidifies the company’s position as a key player in the development and manufacturing of patient-centric infusion solutions. The partnership with the pharmaceutical giant not only validates KORU Medical’s capability as a reliable and innovative technology provider but also reflects the growing demand for patient-focused medical devices.
The collaboration also highlights the significant shift towards personalized medicine and patient-centric healthcare, with healthcare providers and pharmaceutical companies increasingly recognizing the importance of tailoring therapies to individual patient needs. By developing bespoke infusion solutions, KORU Medical demonstrates its commitment to driving innovation and enhancing patient care.
Furthermore, this partnership has the potential to revolutionize the delivery of immunoglobulin therapy by streamlining the treatment process and ultimately improving patient outcomes. The use of KORU Medical’s custom device ensures a consistent and efficient delivery of the novel SCIg drug, minimizing the risk of errors and resulting in improved therapy compliance. Moreover, the subcutaneous route of administration eliminates the need for frequent hospital visits, empowering patients to self-administer treatment in the comfort of their own homes.
The clinical supply agreement with the pharmaceutical partner not only establishes KORU Medical’s credibility within the industry but also positions the company for future growth and expansion. As the market for subcutaneous infusion solutions continues to grow, KORU Medical is well-positioned to capitalize on the increasing demand for innovative and patient-centric devices.
In conclusion, KORU Medical’s clinical supply agreement for a novel subcutaneous immunoglobulin drug entering Phase 3 trials represents a significant milestone for both the company and the broader medical technology industry. By collaborating with a pharmaceutical giant, KORU Medical has solidified its position as a key player in the development and manufacturing of patient-centric large volume subcutaneous infusion solutions. This collaboration not only highlights the increasing demand for personalized medicine and patient-focused healthcare but also has the potential to revolutionize the delivery of immunoglobulin therapy. KORU Medical’s custom device, tailored to the unique needs of the trial, ensures precise and efficient delivery of the novel SCIg drug, ultimately improving patient outcomes and transforming the treatment landscape. With this groundbreaking partnership, KORU Medical is set to lead the way in the future of patient-centric infusion solutions.
Comments